Why has the BARD1 (ASX:BD1) share price vanished from the ASX boards?

Where are BARD1’s shares hiding?

| More on:
A male Avita Medical doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused

Image source: Getty Images

The BARD1 Life Sciences Limited (ASX: BD1) share price isn’t going anywhere on Thursday.

In fact, the BARD1 share price has vanished completely from the ASX boards today.

Where is the BARD1 share price?

The good news is that nothing bad has happened to the BARD1 share price or the company itself.

The reason you can’t see it on the ASX boards is because this morning the company’s name and ticker change came into effect.

Following the approval of shareholders at its annual general meeting at the end of November, the diagnostic and exosome-based products company has now renamed itself INOVIQ Ltd (ASX: IIQ).

Why did BARD1 become INOVIQ?

The company changed its name to INOVIQ as it feels this better reflects the strategic vision, broader intellectual property assets, and its expanded product portfolio since its acquisition of Sienna Cancer Diagnostics in 2020.

This is because the original name of BARD1 related to its BARD1 technology and doesn’t reflect its broader interests across other technologies such as the SubB2M, NETs and hTERT.

INOVIQ’s CEO, Dr Leearne Hinch, explained: “The name change to INOVIQ represents the evolution of the Company’s expanded focus on developing and commercialising innovative diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The new name future-proofs the continued growth and expansion of our business, capabilities, and product portfolio. We thank shareholders for their support of the name change and look forward to unveiling the new brand and website in coming weeks.”

Prior to the name change, the BARD1 share price was up approximately 59% in 2021. Investors will no doubt be hoping the INOVIQ share price picks up from where BARD1 left off.

Should you invest $1,000 in INOVIQ right now?

Before you consider INOVIQ, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and INOVIQ wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares